Approval · Notice of Compliance 1623 · 2004
PHL-INDAPAMIDE: Notice of Compliance 1623
Issued April 14, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1623
- Date
- April 14, 2004
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Product name change from riva-indapamide
- Therapeutic class
- Diuretic, antihypertensive agent
- Canadian reference product
- LOZIDE (Servier Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PHL-INDAPAMIDE | 02240349 | Cancelled Post Market |
| PHL-INDAPAMIDE | 02240350 | Cancelled Post Market |
Medicinal ingredients
- INDAPAMIDE 1.25 MG per TAB
- INDAPAMIDE 2.5 MG per TAB